Regulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression

被引:44
作者
Bao, Dejun [2 ,3 ,4 ]
Cheng, Chuandong [2 ,3 ,4 ]
Lan, Xiaoqiang [1 ,5 ]
Xing, Rong [1 ]
Chen, Zhuo [7 ]
Zhao, Hua [8 ]
Sun, Junyan [1 ]
Wang, Yang [1 ]
Niu, Chaoshi [2 ,3 ,4 ]
Zhang, Bo [5 ]
Fang, Shengyun [6 ]
机构
[1] Dalian Med Univ, Sch Basic Med Sci, Dept Pathophysiol, Dalian, Peoples R China
[2] Anhui Med Univ, Anhui Prov Hosp, Dept Neurosurg, Hefei, Peoples R China
[3] Anhui Prov Stereotact Neurosurg Inst, Hefei, Peoples R China
[4] Anhui Prov Key Lab Brain Funct & Brain Dis, Hefei, Peoples R China
[5] Dalian Med Univ, Hosp 2, Dept Neurosurg, Dalian, Peoples R China
[6] Univ Maryland, Sch Med, Dept Physiol, Ctr Biomed Engn & Technol,Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[7] Anhui Prov Hosp, Anhui Prov Canc Hosp, West Branch, Hefei, Peoples R China
[8] Chinese Acad Sci, Canc Hosp, Dept Clin Lab, Hefei, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
AR signaling; SVIP; cell proliferation; serum testosterone; p53; GLIOBLASTOMA-MULTIFORME; SPLICE VARIANTS; UNITED-STATES; ADULT GLIOMA; PROSTATE; CASTRATION; RESISTANT; SEX; IDENTIFICATION; ENZALUTAMIDE;
D O I
10.18632/oncotarget.15509
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence of glioma in men is higher than that in women; however, little is known about the expression and basic function of the androgen receptor (AR) in gliomas. AR inhibited the small VCP/ p97-interacting protein (SVIP) on the transcriptional level was previously reported. The present study shows that the protein level of AR is highly expressed in cell lines of the nervous system. Moreover, the AR expression is increased while SVIP expression is decreased in tumor tissue of glioma patients, which is in agreement with the progressing WHO grades. A statistically significant increase in serum testosterone level of glioma patients compared with that of non-cancer patients was also detected. Furthermore, it has been proved that SVIP is down-regulated as well as AR is up-regulated in glioma cell lines with R1881 treatment. Interestingly, the depletion of SVIP using siRNA facilitated cell proliferation and decreased p53 expression. In addition, overexpression of SVIP increased cell death only in p53wt cell lines. Moreover, U87MG cells, p53wt cell line was susceptible to AR antagonists in vitro and in vivo. The current study provides insight into the biological role of AR in suppressing SVIP and p53 and promoting the progression of glioma as well as the clinical treatment of glioma patients.
引用
收藏
页码:23142 / 23154
页数:13
相关论文
共 37 条
  • [1] Expression of androgen receptor is negatively regulated by p53
    Alimirah, Fatouma
    Panchanathan, Ravichandran
    Chen, Jianming
    Zhang, Xiang
    Ho, Shuk-Mei
    Choubey, Divaker
    [J]. NEOPLASIA, 2007, 9 (12): : 1152 - 1159
  • [2] Application of Awake Craniotomy and Intraoperative Brain Mapping for Surgical Resection of Insular Gliomas of the Dominant Hemisphere
    Alimohamadi, Maysam
    Shirani, Mohammad
    Moharari, Reza Shariat
    Pour-Rashidi, Ahmad
    Ketabchi, Mehdi
    Khajavi, Mohammadreza
    Arami, Mohamadali
    Amirjamshidi, Abbas
    [J]. WORLD NEUROSURGERY, 2016, 92 : 151 - 158
  • [3] [Anonymous], PLOS ONE
  • [4] Identification of SVIP as an endogenous inhibitor of endoplasmic reticulum-associated degradation
    Ballar, Petek
    Zhong, Yongwang
    Nagahama, Masami
    Tagaya, Mitsuo
    Shen, Yuxian
    Fang, Shengyun
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (47) : 33908 - 33914
  • [5] Estrogen increases survival in an orthotopic model of glioblastoma
    Barone, Tara A.
    Gorski, Justin W.
    Greenberg, Steven J.
    Plunkett, Robert J.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2009, 95 (01) : 37 - 48
  • [6] Vertebrate animal models of glioma: Understanding the mechanisms and developing new therapies
    Chen, Leon
    Zhang, Yuqing
    Yang, Jingxuan
    Hagan, John P.
    Li, Min
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2013, 1836 (01): : 158 - 165
  • [7] Defining human ERAD networks through an integrative mapping strategy
    Christianson, John C.
    Olzmann, James A.
    Shaler, Thomas A.
    Sowa, Mathew E.
    Bennett, Eric J.
    Richter, Caleb M.
    Tyler, Ryan E.
    Greenblatt, Ethan J.
    Harper, J. Wade
    Kopito, Ron R.
    [J]. NATURE CELL BIOLOGY, 2012, 14 (01) : 93 - U176
  • [8] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
    Clegg, Nicola J.
    Wongvipat, John
    Joseph, James D.
    Tran, Chris
    Ouk, Samedy
    Dilhas, Anna
    Chen, Yu
    Grillot, Kate
    Bischoff, Eric D.
    Cal, Ling
    Aparicio, Anna
    Dorow, Steven
    Arora, Vivek
    Shao, Gang
    Qian, Jing
    Zhao, Hong
    Yang, Guangbin
    Cao, Chunyan
    Sensintaffar, John
    Wasielewska, Teresa
    Herbert, Mark R.
    Bonnefous, Celine
    Darimont, Beatrice
    Scher, Howard I.
    Smith-Jones, Peter
    Klang, Mark
    Smith, Nicholas D.
    De Stanchina, Elisa
    Wu, Nian
    Ouerfelli, Ouathek
    Rix, Peter J.
    Heyman, Richard A.
    Jung, Michael E.
    Sawyers, Charles L.
    Hager, Jeffrey H.
    [J]. CANCER RESEARCH, 2012, 72 (06) : 1494 - 1503
  • [9] Brain tumors and hormonal factors: review of the epidemiological literature
    Cowppli-Bony, Anne
    Bouvier, Ghislaine
    Rue, Marjory
    Loiseau, Hugues
    Vital, Anne
    Lebailly, Pierre
    Fabbro-Peray, Pascale
    Baldi, Isabelle
    [J]. CANCER CAUSES & CONTROL, 2011, 22 (05) : 697 - 714
  • [10] Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios G.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (06) : 697 - 707